Alamar Biosciences, Inc. ALMR
30.22 USD +1.28 (+4.42%)
At closeNov 3, 2026, 4:16 PM EST
30.00 -0.22 -0.73%
After hours · Nov 3, 4:16 PM ET
29.18 Day range 30.29
18.85 52-week range 39.61
- YTD
- +37.36%
- 1 year
- +37.36%
Analyst view
Price target (mean) 35.40 +17.1% upside
Now 30.22
- Target (low)
- 31.00
- Target (mean)
- 35.40
- Target (high)
- 45.00
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy1
- Buy3
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.18688 | -0.26 – -0.10 | 0.00 | 0.0% | 30.19M | 0.0% | 4 |
| Next quarter | -0.18492 | -0.24 – -0.13 | 0.00 | 0.0% | 32.88M | 0.0% | 4 |
| Current year | -1.10 | -1.31 – -0.86 | 0.00 | 0.0% | 118.58M | 0.0% | 4 |
| Next year | -0.4518 | -0.90 – -0.12 | -1.10 | +59.0% | 165.71M | +39.8% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 11, 2026 | Stifel | Maintained | Buy | Buy |
| Aug 11, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| May 12, 2026 | Leerink Partners | Initiated | — | Outperform |
| May 12, 2026 | TD Cowen | Initiated | — | Buy |
| May 12, 2026 | JP Morgan | Initiated | — | Overweight |
| May 12, 2026 | Stifel | Initiated | — | Buy |